Literature DB >> 3358797

Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases.

M Tomana1, R E Schrohenloher, W J Koopman, G S Alarcón, W A Paul.   

Abstract

Results of carbohydrate analysis of serum IgG from patients with rheumatoid arthritis (RA) confirmed an earlier report that IgG from patients with RA is galactosylated to a lesser extent than IgG from healthy individuals. In contrast to the previous report, we found that the content of galactose in IgG from controls and RA patients was negatively correlated with age (P = 0.026 and P = 0.010, respectively). In RA patients, the IgG content of galactose was also negatively correlated with the pain index (P less than 0.05) and was lower in the presence of rheumatoid factor (P less than 0.05). No correlation was found between the galactose deficiency of IgG from RA patients and sex, race, duration of disease, packed red blood cell volume, radiographic grade, disability index, extraarticular manifestations, articular erosions, or treatment with steroids. Furthermore, no correlation was found between the galactose content of IgG and serum levels of IgM rheumatoid factor or the ability of IgG to bind IgM rheumatoid factor in vitro. Significant galactose deficiency was also detected in IgG from patients with systemic lupus erythematosus and Crohn's disease, which suggests that the defect in the galactosylation of IgG is a feature common to a variety of chronic inflammatory diseases. The biologic significance of this observation remains unclear.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358797     DOI: 10.1002/art.1780310304

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  45 in total

1.  Second Jenner international glycoimmunology meeting.

Authors: 
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

Review 2.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 3.  The immunology of inflammatory bowel disease.

Authors:  J R Lowes; D P Jewell
Journal:  Springer Semin Immunopathol       Date:  1990

4.  Two-dimensional electrophoresis of synovial tissue, synovial fluid and serum in patients with rheumatoid arthritis and related diseases.

Authors:  P Fritz; N Arold; A Mischlinski; H Wisser; B Oeffinger; V Neuhoff; W Laschner; G Koenig
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

Review 5.  Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis.

Authors:  Florent Colomb; Leila B Giron; Irena Trbojevic-Akmacic; Gordan Lauc; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

6.  The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis.

Authors:  Ewa Gindzienska-Sieskiewicz; Piotr Adrian Klimiuk; Dariusz Gabriel Kisiel; Andrzej Gindzienski; Stanislaw Sierakowski
Journal:  Clin Rheumatol       Date:  2006-08-04       Impact factor: 2.980

Review 7.  Cryoglobulins.

Authors:  C Ferri; A L Zignego; S A Pileri
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

Review 8.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

9.  Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis.

Authors:  Richard Vytásek; Liliana Sedová; Vladimír Vilím
Journal:  BMC Musculoskelet Disord       Date:  2010-05-03       Impact factor: 2.362

10.  Structural changes in the oligosaccharide moiety of human IgG with aging.

Authors:  K Shikata; T Yasuda; F Takeuchi; T Konishi; M Nakata; T Mizuochi
Journal:  Glycoconj J       Date:  1998-07       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.